IDYA
IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Thursday, February 13, 2025 BiopharmaWatch Research 1 min read Key Takeaway: IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Price reaction · baseline $21.95 (2025-02-12 close) · hit after-hours · clean, no other IDYA news in the window
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma
Full Press Release Details
IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update.